Breaking News Instant updates and real-time market news.

ANTM

Anthem

$228.63

6.35 (2.86%)

, CNC

Centene

$99.57

1.76 (1.80%)

12:11
11/29/17
11/29
12:11
11/29/17
12:11

ACA enrollment at 2.8M in first four weeks, Axios reports

Within the first four weeks of open enrollment roughly 2.8M people have signed up for Affordable Care Act coverage for 2018, including nearly 718,000 new customers and about 2.1M renewals, Axios reports, citing figures released by the Centers for Medicare and Medicaid Services. The current enrollment period runs through December 15, half as long as 2017's enrollment period, in which 12.2M people signed up for coverage. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Reference Link

ANTM

Anthem

$228.63

6.35 (2.86%)

CNC

Centene

$99.57

1.76 (1.80%)

HUM

Humana

$249.32

5.1 (2.09%)

MOH

Molina Healthcare

$76.98

1.99 (2.65%)

WCG

WellCare

$209.88

5.77 (2.83%)

CI

Cigna

$205.08

4.53 (2.26%)

HNT

Health Net

AET

Aetna

$179.80

0.9595 (0.54%)

UNH

UnitedHealth

$223.18

7.04 (3.26%)

  • 15

    Dec

ANTM Anthem
$228.63

6.35 (2.86%)

11/09/17
BARD
11/09/17
NO CHANGE
Target $101
BARD
Outperform
Anthem significantly opens access to Sarepta DMD drug, says Baird
Baird analyst Brian Skorney noted that Anthem (ANTM) has reversed course with its new coverage policy for Sarepta's (SRPT) Duchenne muscular dystrophy drug Exondys 51, as the insurer now considers the drug "medically necessary," compared to its prior view of eteplirsen as "investigational and not medically necessary." This is a significant step in the right direction for Sarepta and points to continued progress on the reimbursement front, Skorney tells investors. He maintains an Outperform rating and $101 price target on Sarepta shares.
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
11/07/17
LEER
11/07/17
NO CHANGE
Target $300
LEER
Outperform
Anthem price target raised to $300 from $245 at Leerink
Leerink analyst Ana Gupte raised her price target for Anthem to $300 from $245 as she sees the appointment of Gail Boudreaux as its next CEO as a "strong driver" of multiple expansion. The analyst reiterates an Outperform rating on the shares.
11/03/17
FBCO
11/03/17
INITIATION
Target $234
FBCO
Outperform
Anthem initiated with an Outperform at Credit Suisse
Credit Suisse analyst A.J. Rice started Anthem with an Outperform rating and $234 price target.
CNC Centene
$99.57

1.76 (1.80%)

10/16/17
LEER
10/16/17
NO CHANGE
LEER
Facilities, Centene most structurally impacted to downside in 2019, says Leerink
Leerink analyst Ana Gupte sees the Facilities and Centene (CNC) most structurally impacted to the downside in 2019 and beyond at 15% of earnings, if there is no legislative or other budgetary compromise to restore the Cost Sharing Subsidies after President Trump's executive action to stop funding them. The analyst also notes that Healthcare Facilities also face a structural headwind in 2019 and beyond with Exchanges contributing 1%-5% of EBITDA. In the near-term in 2017, Gupte says Molina Healthcare (MOH) faces transient balance sheet pressure with the Q4 unfunding placing pressure of $135M and wiping excess parent cash possibly necessitating an equity raise, while other HIX plans Anthem (ANTM), Centene and Cigna (CI) can offset with their excess capitalization at the subsidiaries and at the parent.
10/17/17
BMOC
10/17/17
INITIATION
Target $120
BMOC
Outperform
Centene initiated with an Outperform at BMO Capital
BMO Capital analyst Matt Borsch initiated Centene with an Outperform rating and a price target of $120. Borsch cites attractive sector-relative valuation as well as multi-year growth expectations with revenue opportunity above $500B as high-acuity Medicaid populations are brought into managed care.
10/25/17
OPCO
10/25/17
NO CHANGE
Target $111
OPCO
Outperform
Centene price target raised to $111 from $105 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Centene to $111 from $105 following quarterly results. The analyst reiterates an Outperform rating on the shares.
11/03/17
FBCO
11/03/17
INITIATION
Target $102
FBCO
Neutral
Centene initiated with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice started Centene with a Neutral rating and $102 price target.
HUM Humana
$249.32

5.1 (2.09%)

11/10/17
BMOC
11/10/17
NO CHANGE
Target $290
BMOC
Outperform
Humana price target lowered to $290 from $300 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Humana to $290 following Q3 results to account for lower than expected initial FY18 EPS outlook. The analyst attributes some of the caution to increased competition in Medicare, but says the multi-year growth outlook remains strong. Borsch keeps his Outperform rating on Humana, saying the company also remains a possible acquisition target as the only Medicare Advantage pure play.
11/03/17
FBCO
11/03/17
INITIATION
Target $256
FBCO
Neutral
Humana initiated with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice started Humana with a Neutral rating and $256 price target.
10/30/17
LEER
10/30/17
NO CHANGE
LEER
Leerink sees CVS/Aetna as primarily a defensive play
Leerink analyst Ana Gupte sees CVS Health (CVS)-Aetna (AET) as primarily a defensive, not offensive play to fight dual threats of Captive PBMs and Amazon (AMZN) and for Aetna, a response to Optum, Anthem (ANTM) IngenioRx and growth challenges. The analyst expects bio-pharma cost savings for consumers unlikely to improve, with potential loss of health plan business while efficiencies in the specialty pharmacy supply chain through Home Health are not enhanced. Anti-trust approval is possible, but likely challenged by the loss of health plan clients such as Anthem that reduce buying power, Gupte contends, adding that she sees Humana (HUM) merging with Express Scripts (ESRX) and WellCare (WCG) or Humana by Cigna (CI) as the most likely near-term.
MOH Molina Healthcare
$76.98

1.99 (2.65%)

10/16/17
BMOC
10/16/17
INITIATION
Target $70
BMOC
Market Perform
Molina Healthcare initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated LifePoint with an Market Perform and $70 price target due to lack of visibility and until there is more clarity on the scope of the profitability impairment.
10/16/17
PIPR
10/16/17
NO CHANGE
PIPR
Piper a buyer of Centene, Molina after Friday's selloff
Piper Jaffray analyst Sarah James believes Friday's selloff in shares of Centene (CNC) and Molina Healthcare (MOH) caused by President Trump's executive actions is overdone. Both companies are well positioned to handle the Affordable Care Act changes given their focus on lower income/higher subsidy exchange members, James tells investors in a research note. She sees Centene and Molina as less vulnerable to adverse selection risk and is a buyer of both names.
10/23/17
WOLF
10/23/17
UPGRADE
WOLF
Outperform
Molina Healthcare upgraded to Outperform from Peer Perform at Wolfe Research
WCG WellCare
$209.88

5.77 (2.83%)

11/01/17
WELS
11/01/17
NO CHANGE
Target $188
WELS
Market Perform
WellCare price target raised to $188 from $175 at Wells Fargo
Wells Fargo analyst Peter Costa raised his price target for WellCare to $188 from $175 as its Q3 adjusted EPS far exceeded expectations. The analyst reiterates a Market Perform rating on the shares.
11/01/17
PIPR
11/01/17
NO CHANGE
Target $214
PIPR
Overweight
WellCare price target raised to $214 from $199 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for WellCare to $214 saying she'd still be a buyer of the stock post yesterday's rally. The analyst believes 2018 could top consensus expectations and keeps an Overweight rating on the stock.
11/20/17
DBAB
11/20/17
NO CHANGE
Target $240
DBAB
Buy
WellCare price target raised to $240 from $220 at Deutsche Bank
Deutsche Bank analyst Chris Rigg raised his price target for WellCare Health Plans $240 after hosting management for investor meetings in the midwest. Management still sees the company in the earlier stages of establishing the infrastructure for longer-term growth, Rigg tells investors in a research note. He notes that management expects 2019 to be an even stronger year for earnings than 2018. The analyst reiterates a Buy rating on the shares.
CI Cigna
$205.08

4.53 (2.26%)

11/03/17
FBCO
11/03/17
INITIATION
Target $219
FBCO
Outperform
Cigna initiated with an Outperform at Credit Suisse
Credit Suisse analyst A.J. Rice started Cigna with an Outperform rating and $219 price target.
10/16/17
BMOC
10/16/17
INITIATION
Target $210
BMOC
Market Perform
Cigna initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated Cigna with an Market Perform and $210 price target due to its slower-growth commercial mix.Target $210.
HNT Health Net

06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
AET Aetna
$179.80

0.9595 (0.54%)

11/21/17
LEER
11/21/17
NO CHANGE
Target $85
LEER
Outperform
CVS deal with Aetna a long-term positive, says Leerink
Leerink analyst David Larsen believes that a potential CVS (CVS)/Aetna (AET) combination would provide significant long-term value to both shareholders and clients. The analyst believes that CVS may be able to more effectively tie reimbursement to performance for specialty drugs, procurement synergies may exist for Red Oak, and CVS may be able to capture more Aetna volumes. While there would likely be a second request, and lengthy review process, Larsen believes the deal would eventually clear regulatory review. He reiterates an Outperform rating and $85 price target on CVS shares.
11/07/17
JEFF
11/07/17
NO CHANGE
Target $76
JEFF
Buy
Jefferies not seeing multiple expansion for CVS until concerns dissipate
While the stock has come down significantly, overhangs on CVS Health will likely prevent meaningful share upside in the near-term, Jefferies analyst Brian Tanquilut tells investors in a post-earnings research note. He lowered his price target for the shares to $76 from $86 following the company's Q3 results and keeps a Hold rating on the name. Investors seem focused on a potential acquisition of Aetna (AET) and continued risk from Amazon.com (AMZN), Tanquilut contends. He believes these two concerns needs to dissipate before CVS Health's multiple expands.
11/10/17
NEED
11/10/17
UPGRADE
Target $79
NEED
Buy
Needham upgrades CVS to Buy despite potential Amazon threat
Needham analyst Kevin Caliendo upgraded CVS Health (CVS) to Buy from Hold with a $79 price target. The healthcare company closed yesterday up 3c to $69.02. The stock's risk/reward is favorable, especially if CVS is able to consummate the reported merger with Aetna (AET), Caliendo tells investors in a research note. The analyst puts a better than 50/50 chance of Amazon (AMZN) entering the pharmacy market, and sees CVS shares trading down to 9-10 times earnings in a worst case scenario. His best-case scenario has Amazon putting off a decision on pharmacy and CVS buying Aetna. Caliendo thinks CVS' multiple could expand to 14 times or more under his best case.
UNH UnitedHealth
$223.18

7.04 (3.26%)

11/29/17
FBCO
11/29/17
NO CHANGE
Target $240
FBCO
Outperform
UnitedHealth price target raised to $240 from $233 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for UnitedHealth to $240 from $233 after the company strikes a positive tone across the board at its Investor Day. The analyst reiterates an Outperform rating on the shares.
11/29/17
WELS
11/29/17
NO CHANGE
Target $245
WELS
Outperform
UnitedHealth price target raised to $245 from $230 at Wells Fargo
Wells Fargo raised its price target for UnitedHealth to $245 from $230 following the company's annual investor day and to reflect increased confidence in its outlook longer-term. The firm reiterates an Outperform rating on the shares.
11/29/17
CANT
11/29/17
NO CHANGE
Target $235
CANT
Overweight
UnitedHealth price target raised to $235 from $225 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for UnitedHealth to $235 and reiterates an Overweight rating on the shares following yesterday's annual investor conference. UnitedHealth offered a clear message that its investments in digital technologies "should permit strong health-plan performance in the future," Halper tells investors in a research note. The analyst continues to believe the company is uniquely positioned to benefit from the transition to value-based care.
11/29/17
RBCM
11/29/17
NO CHANGE
Target $244
RBCM
Outperform
UnitedHealth price target raised to $244 from $215 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on UnitedHealth to $244 and kept his Outperform rating after the company's FY18 outlook. Morgan says UnitedHealth is well positioned across its business lines and should continue to exceed market growth rates. The analyst expects the stock to continue to attract investor attention and garner premium valuation based on its "solid balance sheet and shareholder-friendly capital deployment".

TODAY'S FREE FLY STORIES

NNBR

NN, Inc.

$26.60

-0.25 (-0.93%)

11:12
12/12/17
12/12
11:12
12/12/17
11:12
Conference/Events
NN, Inc. management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VMC

Vulcan Materials

$122.21

-0.715 (-0.58%)

11:07
12/12/17
12/12
11:07
12/12/17
11:07
Conference/Events
Vulcan Materials management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.64

0.62 (4.13%)

11:05
12/12/17
12/12
11:05
12/12/17
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGU

Agrium

$110.72

2.71 (2.51%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Hot Stocks
Agrium to acquire Louis Dreyfus Company's Macrofertil fertilizer business »

Agrium announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Upgrade
Spark Therapeutics rating change  »

Follow-up: Spark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GRPN

Groupon

$5.86

0.05 (0.86%)

10:57
12/12/17
12/12
10:57
12/12/17
10:57
Recommendations
Groupon analyst commentary  »

Groupon selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$51.62

0.19 (0.37%)

10:55
12/12/17
12/12
10:55
12/12/17
10:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

10:55
12/12/17
12/12
10:55
12/12/17
10:55
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

10:54
12/12/17
12/12
10:54
12/12/17
10:54
Upgrade
Spark Therapeutics rating change  »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GSK

GlaxoSmithKline

$35.53

0.22 (0.62%)

10:53
12/12/17
12/12
10:53
12/12/17
10:53
Hot Stocks
FDA approves expanded use of GlaxoSmithKline's Nucala »

The FDA expanded the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TRIP

TripAdvisor

$35.32

0.82 (2.38%)

10:48
12/12/17
12/12
10:48
12/12/17
10:48
Hot Stocks
TripAdvisor, ReviewPush form licensing partnership for restaurant reviews »

ReviewPush announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$55.00

9.925 (22.02%)

, MS

Morgan Stanley

$53.09

0.32 (0.61%)

10:46
12/12/17
12/12
10:46
12/12/17
10:46
Hot Stocks
Overstock rises after Morgan Stanley discloses stake ahead of crypto launch »

Shares of Overstock…

OSTK

Overstock.com

$55.00

9.925 (22.02%)

MS

Morgan Stanley

$53.09

0.32 (0.61%)

BTC

Bitcoin

BITCOIN

Bitcoin

QVCA

QVC Group

$24.52

-0.27 (-1.09%)

TJX

TJX

$73.55

0.25 (0.34%)

COST

Costco

$188.86

0.79 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

, EA

Electronic Arts

$107.92

2.65 (2.52%)

10:44
12/12/17
12/12
10:44
12/12/17
10:44
Hot Stocks
Goldman ups Activision Blizzard, cuts EA in video game ratings shuffle »

Ahead of 2018, Goldman…

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

EA

Electronic Arts

$107.92

2.65 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

TMUS

T-Mobile

$63.07

0.53 (0.85%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Conference/Events
T-Mobile to host business news update conference call »

T-Mobile's President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MMM

3M

$236.76

-2.54 (-1.06%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Recommendations
3M analyst commentary  »

3M guidance solid versus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SQ

Square

$39.23

0.9318 (2.43%)

10:40
12/12/17
12/12
10:40
12/12/17
10:40
Options
Sizable put buyer in Square as shares rally »

Sizable put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

WWE

WWE

$30.94

0.24 (0.78%)

10:37
12/12/17
12/12
10:37
12/12/17
10:37
Conference/Events
WWE management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VKTX

Viking Therapeutics

$3.97

-0.11 (-2.70%)

10:35
12/12/17
12/12
10:35
12/12/17
10:35
Conference/Events
Viking Therapeutics management to meet with Maxim »

Meetingsto be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

  • 28

    Dec

TSLA

Tesla

$328.91

13.78 (4.37%)

, PEP

PepsiCo

$117.97

0.58 (0.49%)

10:34
12/12/17
12/12
10:34
12/12/17
10:34
Hot Stocks
Tesla jumps as PepsiCo makes biggest public pre-order of Semi trucks »

Shares of Tesla (TSLA)…

TSLA

Tesla

$328.91

13.78 (4.37%)

PEP

PepsiCo

$117.97

0.58 (0.49%)

WMT

Walmart

$97.02

0.09 (0.09%)

DPSGY

Deutsche Post

$47.34

-0.26 (-0.55%)

JBHT

J.B. Hunt

$111.30

-1.21 (-1.08%)

BUD

AB InBev

$111.30

-0.12 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Jan

  • 20

    Feb

NICE

Nice

$87.68

-0.15 (-0.17%)

10:32
12/12/17
12/12
10:32
12/12/17
10:32
Conference/Events
Nice management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 26

    Feb

EA

Electronic Arts

$107.92

2.65 (2.52%)

10:30
12/12/17
12/12
10:30
12/12/17
10:30
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

10:30
12/12/17
12/12
10:30
12/12/17
10:30
General news
Euro$ interest rate futures are lower »

Euro$ interest rate…

IPGP

IPG Photonics

$206.65

1.39 (0.68%)

10:29
12/12/17
12/12
10:29
12/12/17
10:29
Conference/Events
IPG Photonics management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

EVI

EnviroStar

$31.45

0.85 (2.78%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Hot Stocks
EnviroStar declares 12c per share special cash dividend »

EnviroStar announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KMT

Kennametal

$45.81

-0.15 (-0.33%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Conference/Events
Kennametal to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.